Anavex Life Sciences (US:AVXL) Globenewswire·2025-11-25 12:30Core Viewpoint - Anavex Life Sciences Corp. reported its financial results for the fourth quarter of fiscal 2025, highlighting its focus on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease, and the progress of its lead drug candidate, blarcamesine [2][3]. Financial Highlights - Cash and cash equivalents stood at $102.6 million as of September 30, 2025, down from $132.2 million a year earlier, with a current cash balance of over $120 million, indicating a cash runway of more than three years [11]. - Research and development expenses for the quarter were $7.3 million, a decrease from $11.6 million in the same quarter of fiscal 2024 [11]. - General and administrative expenses increased to $3.5 million from $2.7 million year-over-year [11]. - The net loss for the quarter was $9.8 million, or $0.11 per share, compared to a net loss of $11.6 million, or $0.14 per share in the fourth quarter of fiscal 2024 [11]. Recent Corporate Developments - Anavex announced a negative trend vote from the CHMP regarding the Marketing Authorisation Application for blarcamesine, with plans to request a re-examination [11]. - The company is advancing its clinical pipeline, including updates on blarcamesine for early Alzheimer's disease, Parkinson's disease, and Rett syndrome, as well as the development of ANAVEX3-71 for schizophrenia [6][11]. - New scientific findings related to blarcamesine's effects on cognitive function and brain atrophy were presented, reinforcing its therapeutic potential [6][11]. Expected Development Milestones - Anavex is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its ongoing commitment to addressing unmet needs in neurodegenerative disorders [11].